EG LEASING's subsidiary plans to sell 103 properties to Solarbio

According to the announcement from Hengjia Financing Leasing (00379), after fair negotiation among the contracting parties, on September 9, 2025, the company's indirect wholly-owned subsidiary Shanghai Lizu Biotechnology, as the seller, entered into a termination agreement with Ginosar, and both parties agreed to terminate the old agreement from the date of the termination agreement; and within 7 days after Solabao (the buyer under the new agreement and five agreements) receives the new consideration, the seller will refund Ginosar the initial deposit of RMB 1.2592 million (equivalent to approximately HKD 1.372 million) that was initially paid to the seller under the old agreement.

On September 9, 2025, the seller agreed to sell, and Solabao agreed to purchase 103 properties, with the new consideration being RMB 6.3682 million (equivalent to approximately HKD 6.941 million). Solabao is also the buyer under the five agreements. For further details regarding the five agreements, please refer to the company's announcement dated August 22, 2025. Given that both the new agreement and the five agreements are entered into with Solabao and will be completed within 12 months, according to Listing Rule 14.22, the sale of the 103 properties and those properties shall be aggregated as if it were a single transaction.

The new consideration of RMB 6.3682 million (equivalent to approximately HKD 6.941 million) under the new agreement is higher than the consideration under the old agreement. In addition, the group will also receive the new consideration in full after entering into the new agreement, and there are no significant costs arising from the termination of the old agreement.

The board of directors believes that the terms and conditions of the termination agreement and the new agreement are established on normal commercial terms, are fair and reasonable, and are in the overall interests of the company and its shareholders